Preparation and anti-malaria application of 4-O-methyl honokiol

By extracting and preparing compounds 4-O-methyl and Magnolia officinalis from Rhodiola plants, combined with conventional drug carriers, the problem of unreported antimalarial activity of Rhodiola was solved, and effective antimalarial treatment effect was achieved .

CN118955258APending Publication Date: 2024-11-15DALI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411172970.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The antimalarial activities of the compounds 4-O-methyl and Magnolol in the long-whip Rhodiola and its compounds 4-O-methyl and Magnolol have not been reported, and the prior art has failed to effectively utilize its pharmacological effects of antimalaria.

Method used

Compounds 4-O-methyl and Magnolia cerol were prepared by extracting the roots or rhizomes or whole plants using organic solvents, combined with column chromatography and liquid-liquid extraction techniques, and used as active ingredients with Conventional pharmaceutical carrier combinations for the preparation of antimalarial agents.

Benefits of technology

The significant activity of the compounds 4-O-methyl and Magnolol in antimalaria has been achieved, providing a new antimalarial pharmaceutical composition with good therapeutic effects, suitable for oral, nasal inhalation, rectal or gastrointestinal External administration method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
  • Figure QLYQS_1
    Figure QLYQS_1
Patent Text Reader

Abstract

The invention relates to preparation of a 3, 3 '-neolignan compound 4-O-methyl honokiol and application of the 3, 3'-neolignan compound 4-O-methyl honokiol in preparation of anti-malarial products, and belongs to the pharmaceutical field of traditional Chinese medicines and natural medicines. The compound 4-O-methyl honokiol provided by the invention is used as an anti-malarial drug of an active ingredient. According to the invention, the medicinal value of the 3, 3 '-neolignan compound in the rhodiola rosea is expanded.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of traditional Chinese medicine and natural medicine pharmaceuticals, and specifically relates to the preparation of a 3,3'-neolignan compound 4-O-methylhonokiol, a drug combination with the compound as an active ingredient, and the application of the drug in an antimalarial agent. Background Art

[0002] Rhodiola rosea ( Rhodiola fastigiate (Hook. f. et Thoms.) SH Fu), also known as broad-leaved rhodiola, vertical branched sedum, Dali sedum, belongs to the genus Rhodiola ( Rhodiola ) plant, is a perennial herb, the whole herb is used for medicinal purposes; it is produced in Tibet, Yunnan, Sichuan and other places in my country, grows in high mountain gravel at an altitude of 2500-5400 meters, and is also distributed in Kashmir, Nepal, Sikkim and Bhutan. The "Sichuan Tibetan Medicinal Materials Standard (2020 Edition)" records that Rhodiola rosea tastes astringent, sweet, bitter, and cool in nature; it has the function of clearing heat and benefiting the lungs, and is used to treat lung heat caused by colds, tracheitis, and bad breath. The "Yunnan Traditional Chinese Medicine Resources Catalog" records that it has the effect of treating trauma. Literature reports that Rhodiola rosea can also treat blood stasis, swelling and trauma (Application of microscopy in authentication of traditional Tibetan medicinal plants of five Rhodiola (Crassulaceae) alpine species by comparative anatomyand micromorphology. Microscopy Research and Technique , 2008, 71(6): 448-458). In recent years, there have been few studies on the chemical components of Rhodiola rosea, and its pharmacological activity is also rare. Modern pharmaceutical research shows that Rhodiola rosea contains a variety of chemical components such as organic phenolic acids, glycosides, flavonoids, volatile oils, steroids and trace elements, some of which have the effects of delaying body aging, scavenging free radicals, preventing and treating senile diseases, anti-oxidation, anti-fatigue, antibacterial, anti-viral and immunomodulatory (Research Overview of Rhodiola rosea. Tibet Science and Technology , 2009, 26(4): 73-78). However, there is no report on the antimalarial activity of Rhodiola rosea and its compound 4-O-methylhonokiol so far. Summary of the invention

[0003] The present invention aims to provide a preparation method of 3,3'-neolignan compound 4-O-methylhonokiol, a pharmaceutical composition with the 4-O-methylhonokiol as an active ingredient, and application of the 4-O-methylhonokiol in the preparation of antimalarial agents.

[0004] The above object of the present invention is achieved through the following technical solutions: The 3,3'-neolignan compound 4-O-methylhonokiol shown in the following structure, .

[0005] The preparation method of 4-O-methylhonokiol comprises taking Rhodiola rosea ( Rhodiola ) The root, rhizome or whole plant of the plant is directly cold-soaked or hot-refluxed with an organic solvent such as petroleum ether or chloroform or ethyl acetate or acetone or methanol or ethanol or water, or first cold-soaked or refluxed with the above organic solvents or water and then extracted with petroleum ether or ethyl acetate to obtain a total extract, and the total extract is subjected to repeated column chromatography to obtain the compound 4-O-methylhonokiol.

[0006] The preparation method of the compound 4-O-methylhonokiol of the present invention is more specifically using: A: The root, rhizome or whole plant of Rhodiola rosea is extracted by cold soaking or hot reflux extraction with acetone, methanol, ethanol or water to obtain a total extract, which is then extracted with petroleum ether or ethyl acetate to obtain the corresponding extract, and the compound 4-O-methylhonokiol can be obtained by repeated column chromatography.

[0007] B: The roots, rhizomes or whole plant powder of Rhodiola rosea can be directly extracted by cold soaking or hot reflux extraction with organic solvents (such as methanol, ethanol, acetone, ethyl acetate, petroleum ether, chloroform) to obtain a total extract, which can be subjected to repeated column chromatography to obtain the compound 4-O-methylhonokiol.

[0008] More specifically, the preparation method of the compound 4-O-methyl honokiol is to dry the root or rhizome or the whole plant of the genus Rhodiola in the shade, crush it into 20-30 mesh, extract it with 95% ethanol at room temperature for 3 times, each time for 24 hours, combine the extracts, concentrate the extracts under reduced pressure to obtain an extract, and then extract it with solid phase extraction or liquid-liquid extraction using petroleum ether or ethyl acetate as an extraction solvent to obtain a corresponding extract, dissolve the extracted part with an appropriate amount of chloroform / acetone, mix the sample with 80-100 mesh silica gel, and then use 200-300 mesh silica gel for column chromatography to segment and roughly separate, and use petroleum ether / ethyl acetate 100:1-50:1 or petroleum ether / acetone 100:1-50:1 gradient elution, identify and merge 9 components after thin layer chromatography, and repeatedly perform silica gel column chromatography, MCI column chromatography and Sephadex LH-20 column chromatography on component 8 to obtain the compound 4-O-methyl honokiol.

[0009] An antimalarial agent comprising the compound 4-O-methylhonokiol and conventional adjuvants.

[0010] The pharmaceutical composition contains a therapeutically effective amount of the compound 4-O-methylhonokiol and a pharmaceutically acceptable carrier.

[0011] Application of the compound 4-O-methylhonokiol in the preparation of antimalarial agents.

[0012] The anti-malarial pharmaceutical composition of the present invention contains the compound 4-O-methylhonokiol and a pharmaceutically acceptable carrier.

[0013] The pharmaceutically acceptable carrier in the pharmaceutical composition of the present invention refers to a conventional pharmaceutical carrier in the pharmaceutical field. The compound of the present invention can be administered to patients in need of such treatment in the form of a composition by oral administration, nasal inhalation, rectal administration or parenteral administration. When used for oral administration, it can be made into a conventional solid preparation such as tablets, powders, granules, capsules, etc., or into a liquid preparation such as oil suspension, syrup, elixir, etc.; when used for parenteral administration, it can be made into a solution for injection, etc. The preferred forms are tablets, capsules and injections.

[0014] The various dosage forms of the pharmaceutical composition of the present invention can be prepared according to conventional production methods in the pharmaceutical field, for example, by mixing the active ingredient with one or more carriers and then preparing the mixture into the desired dosage form.

[0015] The pharmaceutical composition of the present invention preferably contains 0.1% to 99.5% by weight of the active ingredient, and most preferably contains 0.5% to 95% by weight of the active ingredient.

[0016] The dosage of the compound of the present invention may vary according to the route of administration, the patient's age, body weight, the type and severity of the disease to be treated, etc. The daily dose may be 0.01-10 mg / kg body weight, preferably 0.1-5 mg / kg body weight. It may be administered once or multiple times.

[0017] The compounds of the present invention show good antimalarial activity.

[0018] The present invention screens the antimalarial activity of the compound 4-O-methyl honokiol, and the compound shows good antimalarial activity. In the antimalarial activity application, the compound 4-O-methyl honokiol is applied to a substrate or a population in an amount ranging from 1 to 1000 μM, preferably from 10 to 200 μM, and is optionally combined with a carrier and / or a medium. DETAILED DESCRIPTION

[0019] The following embodiments of the present invention are used to further illustrate the essential content of the present invention, so that professionals can understand the present invention more comprehensively, but the present invention is not limited in any way. Embodiment 1:

[0020] Extraction, separation and purification of the compound 4-O-methylhonokiol of the present invention: The whole plant of Rhodiola rosea (9.36 kg) was dried in the shade, crushed to 20-30 mesh, and extracted with 95% ethanol at room temperature for 3 times, 50 L for 24 h each time. The extracts were combined, and the extracts were concentrated under reduced pressure to obtain an extract, and then solid phase extraction was performed with petroleum ether to obtain a petroleum ether extract (22.5 g). The petroleum ether extract was dissolved with an appropriate amount of chloroform / acetone and mixed with 80-100 mesh silica gel, and then column chromatography was performed with about 10 times the sample amount of silica gel 200-300 mesh for rough separation, and petroleum ether / ethyl acetate 100:1-50:1 gradient elution was performed, and 9 components were obtained by thin layer chromatography. Component 8 was repeatedly subjected to silica gel column chromatography to obtain compound 4-O-methylhonokiol. Embodiment 2:

[0021] The physical and spectral data of the compound 4-O-methylhonokiol of the present invention are as follows: 4-O-Methylhonokiol: yellow oily liquid. 1 H-NMR (400 MHz, CDCl 3 ) δ : 7.29 (1H, dd, J = 8.3, 2.3 Hz, H-4'), 7.23 (1H, d, J = 2.3 Hz, H-6'), 7.05 (1H, dd, J =8.1, 2.2 Hz, H-2), 7.03 (1H, d, J = 2.2Hz, H-6), 6.96 (1H, d, J = 8.3 Hz, H-3'), 6.91 (1H, d, J = 8.1 Hz, H-3), 5.92-6.06 (2H, m, H-8, H-8'), 5.04-5.15(5H, m, H-9, H-9' ,2'-OH), 3.38 (3H, s, 4-OMe), 3.44 (2H, d, J = 6.7 Hz, H-7), 3.35 (2H, d, J = 6.7 Hz, H-7'); 13 C-NMR (100 MHz, CDCl 3 ) δ: 129.1 (s, C-1),130.6 (d, C-2), 128.9 (d, C-3), 157.1 (s, C-4), 129.9 (s, C-5), 128.0 (d, C-6), 34.4 (t, C-7), 136.6 (d, C-8), 115.7 (t, C-9), 127.9 (s, C-1'), 150.9 (s,C-2'), 111.1 (d, C-3'), 115.6 (d, C-4'), 132.2 (s, C-5'), 130.3 (d, C-6'),39.6 (t, C-7'), 137.9 (d, C-8'), 116.0 (t, C-9'), 55.7 (s, 4-OMe). Embodiment 3:

[0022] Antimalarial activity test of the compounds of the present invention: The SYBR Green I method was used to evaluate the anti-Plasmodium falciparum activity of the compounds of the present invention in vitro. Plasmodium falciparum Plasmodium was cultured in RPMI 1640 medium with a human hematocrit of 2% at 37°C and CO 2 The concentration is 5%. The malarial parasites used in the experiment were synchronized to the ring stage with 5% sorbitol. The malarial parasite infection rate in the final detection system was 1% and the hematocrit was 2%. The above-mentioned ring stage malarial parasites and the test compound were co-cultured in a 96-well plate for 72 hours, and the fluorescent dye SYBR Green I was added. Finally, the growth of malarial parasites was detected by measuring the fluorescence value (excitation: 485 nm, emission: 535 nm) by an enzyme reader. The inhibition rate was calculated according to the following formula: Plasmodium inhibition rate (%) = (fluorescence value of negative control group - fluorescence value of test sample group) / (fluorescence value of negative control group - fluorescence value of blank group) × 100%.

[0023] The activity data are shown in Table 1.

[0024]

[0025] Embodiment 4: Tablets: 10 mg of the compound 4-O-methylhonokiol obtained in Examples 1 and 2, 180 mg of lactose, 55 mg of starch, and 5 mg of magnesium stearate; Preparation method: The compound, lactose and starch are mixed, and evenly moistened with propylene glycol. The moistened mixture is sieved and dried, and then sieved again. Magnesium stearate is added, and then the mixture is compressed into tablets. Each tablet weighs 250 mg and contains 10 mg of the compound.

[0026] Embodiment 5: Ampoule: 2 mg of the compound 4-O-methylhonokiol obtained in Examples 1 and 2; Preparation method: The compound 4-O-methylhonokiol obtained in Examples 1 and 2 was dissolved in 3 mL of propylene glycol, the resulting solution was filtered, and filled into an ampoule bottle under sterile conditions.

[0027] Embodiment 6: Capsules: 10 mg of the compound 4-O-methylhonokiol obtained in Examples 1 and 2, 187 mg of lactose, and 3 mg of magnesium stearate; Preparation method: The compound is mixed with the auxiliary agent, sieved, and mixed evenly. The resulting mixture is filled into hard gelatin capsules, each capsule weighing 200 mg and containing 10 mg of active ingredient.

Claims

1. A method for preparing the compound 4-O-methylhonokiol of the following structural formula: .

2. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

3. An antimalarial agent comprising the compound according to claim 1 and conventional adjuvants.

4. Use of the compound according to claim 1 in the preparation of antimalarial agents.